EEF1E1 Knockout A-549 Polyclonal Cells comprise a population of human lung carcinoma epithelial cells engineered via CRISPR/Cas9-mediated disruption of the EEF1E1 gene. This product provides a heterogeneous pool of edited cells, enabling the study of gene function without the limitations of clonal selection. The polyclonal format preserves genetic diversity and allows researchers to assess loss-of-function effects in a context mirroring native tumor heterogeneity.
The A-549 parental cell line (ATCC CCL-185) is an established model for human lung adenocarcinoma, characterized by a KRAS G12S activating mutation and wild-type TP53 status. These cells exhibit alveolar epithelial type II features, making them relevant for studies of non-small cell lung cancer biology, drug responses, and oncogenic signaling. The KRAS mutation drives constitutive MAPK and PI3K pathway activity, while functional p53 retains regulation of apoptosis and cell cycle arrest.
EEF1E1 (also known as AIMP3) encodes a scaffold protein essential for the assembly and stability of the multi-aminoacyl-tRNA synthetase complex, which delivers charged tRNAs to the ribosome during translation elongation. Beyond its housekeeping role, EEF1E1 functions as a potential tumor suppressor by activating TP53 in response to DNA damage, thereby inducing cell cycle arrest and apoptosis. The activity of EEF1E1 is transcriptionally regulated by TP53 and MYC, placing it within a feedback loop that monitors translational fidelity and genomic integrity. EEF1E1 interacts directly with AIMP1, AIMP2, and several synthetases including EPRS, MARS, and KARS to coordinate protein synthesis. Disruption of this gene impairs the assembly of the eEF1 complex, leading to dysregulated translation and attenuation of the p53-mediated stress response.
In the context of A-549 cells with oncogenic KRAS signaling, loss of EEF1E1 is predicted to exacerbate the malignant phenotype by compromising protein quality control and suppressing p53-dependent tumor suppression. This polyclonal knockout model reflects the clonal heterogeneity of tumors and is suitable for investigating how translation elongation defects contribute to lung adenocarcinoma progression. The interplay between compromised EEF1E1 function and KRAS-driven proliferation may identify new vulnerabilities or mechanisms of drug resistance, particularly under genotoxic stress.
This polyclonal knockout cell population is a versatile tool for delineating the tumor-suppressive roles of EEF1E1 in lung cancer, enabling studies of global protein synthesis rates via puromycin incorporation, assessment of tRNA charging states, and co-immunoprecipitation of the multi-synthetase complex. The model can be employed to probe DNA damage signaling cascades using Western blotting for phosphorylated p53 and ??-H2AX, or to evaluate apoptosis and proliferation changes through flow cytometry and incucyte assays. Additionally, it is suitable for drug sensitivity screens to identify compounds that exploit synthetically lethal interactions with EEF1E1 loss. For more information or to discuss your specific application, please contact Ascent Research.
